Loading...

Home
ETF
ALT

ALT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ALT News

Altimmune Releases New Data on Pemvidutide for MASH Treatment

1d agoNASDAQ.COM

Altimmune's Pemvidutide Shows Significant Metabolic Risk Improvements

2d agoNewsfilter

Truist Initiates Coverage on VKTX with Buy Rating and $83 Price Target

2d agostocktwits

Altimmune to Participate in Upcoming Investor Conferences

3d agoNewsfilter

Altimmune Q1 2026 Earnings Call Insights

May 14 2026seekingalpha

Altimmune Reports Q1 2026 Financial Results and Progress on Pemvidutide

May 13 2026Yahoo Finance

SureNano Science Develops Next-Gen GLP-1 Therapy GEP-44

May 13 2026Globenewswire

Altimmune Q1 Earnings Beat Expectations with Strong Cash Position

May 13 2026seekingalpha

Altimmune to Announce Q1 Earnings on May 13

May 12 2026seekingalpha

Altimmune to Report Q1 2026 Financial Results on May 13

May 06 2026Newsfilter

Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings

Apr 28 2026stocktwits

Lululemon's New CEO Announcement Triggers Stock Decline

Apr 24 2026stocktwits

Altimmune Prices $225 Million Public Offering at 13.5% Discount

Apr 23 2026stocktwits

Altimmune Prices Oversubscribed $225 Million Public Offering

Apr 23 2026NASDAQ.COM

Altimmune Prices Oversubscribed Public Offering Raising $225 Million

Apr 23 2026seekingalpha

Altimmune Prices $225 Million Public Offering for Pemvidutide Development

Apr 23 2026Newsfilter